Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966P. Wolkenstein, Christina Bergqvist, Amandine Servy et al.|Orphanet Journal of Rare Diseases|2020Cited by 188
Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1Audrey Sabbagh, P. Wolkenstein, Patrick Aubourg et al.|Human Molecular Genetics|2009Cited by 147
Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a TrialO. Zehou, P. Wolkenstein, S. Ferkal et al.|Journal of Investigative Dermatology|2018Cited by 26
At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control StudyÉ. Sbidian, Sylvie Bastuji‐Garin, L. Valeyrie‐Allanore et al.|Orphanet Journal of Rare Diseases|2011Cited by 23
Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patientsChristina Bergqvist, L. Fertitta, Khaled Ezzedine et al.|Journal of the European Academy of Dermatology and Venereology|2022Cited by 3